Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 30, 2007, and May 31, 2007, for Protalix Biotherapeutics, Inc., a biopharmaceutical company incorporated in Florida with principal executive offices in Carmiel, Israel. The report details the entry into a material definitive agreement and the departure of a director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and contractual agreements rather than financial performance results.
Material Changes
- Scientific Advisory Board Appointment: On May 31, 2007, the Company entered into an agreement with Ernest Beutler, M.D., to serve on its Scientific Advisory Board. His compensation includes an annual cash fee of $18,000 (payable semi-annually) and a grant of 8,000 restricted shares of common stock vesting over four years.
- Director Resignation: On May 30, 2007, Pinhas Barel Buchris resigned from the Board of Directors effective immediately. The resignation was due to his appointment as Director General of the Israeli Ministry of Defense.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding future performance. The primary risk disclosed relates to the loss of a board member due to government service obligations, though the Company has simultaneously added a high-profile scientific advisor to its board.
Key Facts for Investor Verification
- Verify the vesting schedule and fair value of the 8,000 restricted shares granted to Dr. Beutler under the 2006 Stock Incentive Plan.
- Confirm the impact of Dr. Buchris's resignation on the composition and quorum of the Board of Directors.
- Review the full text of the Scientific Advisory Board Agreement (Exhibit 10.1) for any additional obligations or termination clauses.